| CPC C12Q 1/6883 (2013.01) [G16B 20/20 (2019.02); G16B 40/00 (2019.02); G16H 50/30 (2018.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/172 (2013.01)] | 9 Claims |
|
1. A method for a cardiovascular risk assessment in a human subject, the method comprising steps of:
a) determining in a sample isolated from said human subject a presence of a polymorphism at position 27 within each nucleic acid sequence set forth in SEQ ID NOs: 2, 3, 4, 5, 7, 8, 9, 10, 11 or 16, 12, and 35, wherein a presence at position 27 of a C in SEQ ID NO: 2, T in SEQ ID NO: 3, C in SEQ ID NO: 4, C in SEQ ID NO: 5, T in SEQ ID NO: 7, G in SEQ ID NO: 8, A in SEQ ID NO: 9, A in SEQ ID NO: 10, A in SEQ ID NO: 11 or A in SEQ ID NO: 16, G in SEQ ID NO: 12, and T in SEQ ID NO: 35 is indicative of an elevated risk of having a cardiovascular event;
b) based on the presence of the polymorphisms determined in step a), selecting the human subject as having an elevated risk of a cardiovascular event; and
c) administering to the selected human subject an agent with hypolipemic capabilities, an anticoagulant, an antiplatelet agent, a thrombolytic agent, an antithrombotic, an antiarrhythmic agent, an agent that prolongs repolarization, an antihypertensive agent, a vasodilator, a diuretic, an inotropic agent, and/or an antianginal agent.
|